Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ImmunoGen Gains Momentum On Success Of T-DM1, The Herceptin Conjugate In Development By Roche/Genentech

This article was originally published in The Pink Sheet Daily

Executive Summary

Buoyed by the affirmation of its conjugation technology brought by the imminent filing of T-DM1, ImmunoGen is focused on building an internal pipeline with future emphasis co-development deals, not just outlicensing.

You may also be interested in...



Roche's T-DM1 Early Filing Strategy Backfires As FDA Refuses To File BLA

It hasn't been a swell summer for Roche, and now a bit of near-term pipeline news that could have put the company on a more positive trajectory has fallen flat. FDA refused to file Roche's BLA for breast cancer agent trastuzumab-DM1 (T-DM1), a conjugated version of Herceptin, for accelerated approval, the company announced Aug. 27

Roche's T-DM1 Early Filing Strategy Backfires As FDA Refuses To File BLA

It hasn't been a swell summer for Roche, and now a bit of near-term pipeline news that could have put the company on a more positive trajectory has fallen flat. FDA refused to file Roche's BLA for breast cancer agent trastuzumab-DM1 (T-DM1), a conjugated version of Herceptin, for accelerated approval, the company announced Aug. 27

Roche's T-DM1 Early Filing Strategy Backfires As FDA Refuses To File BLA

FDA refused to file Roche's BLA for breast cancer agent trastuzumab-DM1, a conjugated version of Herceptin, for accelerated approval, the company announced Aug. 27.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070863

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel